ALRTF on OTC
ALR Technologies SG Ltd.
$0.01 up 0.00 (0.00%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 16, 2026.
Overview
-$22.1MNet income, fiscal 20253
Compare with enVVeno Medical Corp, Odyssey Health, Inc. or VIVOS INC, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2023
Where the money goes
Where each dollar of revenue went, fiscal 2023
- Cost of revenue0¢$22.1K
- Research and development21¢$1.4M
- Selling, general and admin40¢$2.6M
- Interest39¢$2.5M
Out of $25.5K in revenue.3 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $25.5K | ||
| Cost of revenue | -$22.1K | ||
| Gross Margin | $3.4K | ||
| Product development costs | $793.3K | $883.9K | $1.4M |
| Professional fees | $617.7K | $512.6K | $814.7K |
| Selling, general and administrative expense | $1.5M | $2.0M | $2.6M |
| Total operating expenses | $2.9M | $3.4M | $4.8M |
| Loss before other items | -$2.9M | -$3.4M | -$4.8M |
| Interest expense | -$19.7M | -$12.4M | -$2.5M |
| Foreign exchange loss | -$246.2K | ||
| Write-off of accounts receivable | -$41.1K | ||
| Write-off of accounts payable | $805.5K | ||
| Loss on settlement of debt | -$139.0K | ||
| Total other items | -$19.2M | -$12.5M | -$2.7M |
| Net Loss | -$22.1M | -$15.9M | -$7.5M |
| Exchange difference on translating foreign operations | -$7.0K | ||
| Comprehensive loss for the year | -$22.1M | -$15.9M | -$7.5M |
| Weighted Average Number of Shares Outstanding, Diluted | 607.0M shares | 598.9M shares | 581.0M shares |
| Earnings Per Share, Diluted | -$0.04 | -$0.03 | -$0.01 |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash | $20.3K | $40.7K |
| Inventory | $10.8K | $10.9K |
| Prepaid expenses | $16.2K | $28.0K |
| Total assets | $47.4K | $79.5K |
| Accounts payable and accrued liabilities | $1.4M | $2.0M |
| Promissory notes payable to related parties | $3.1M | $4.2M |
| Promissory notes payable | $2.2M | $2.2M |
| Interest payable to related parties | $2.5M | $2.2M |
| Interest payable | $3.7M | $3.5M |
| Lines of credit from related parties | $23.2M | $19.9M |
| Loan payable to related parties | $3.8M | $2.4M |
| Total liabilities | $39.9M | $36.3M |
| Ordinary shares | $31.5M | $31.3M |
| Additional paid-in capital | $86.7M | $68.5M |
| Accumulated other comprehensive loss cumulative translation differences | -$844 | -$844 |
| Accumulated deficit | -$158.0M | -$136.0M |
| Total shareholders deficit | -$39.9M | -$36.2M |
| Total liabilities and shareholders deficit | $47.4K | $79.5K |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$22.1M | -$15.9M | -$7.5M |
| Share-based compensation included in product development costs, selling, general and administrative expense, professional fees and interest expense | $18.3M | $11.5M | $2.9M |
| Interest expense on lines of credit | $1.8M | $1.7M | $1.6M |
| Payment of lines of credit interest | -$276.6K | -$257.7K | -$310.6K |
| Accrued interest, borrowing costs and interest accretion on loans payable | $40.0K | $307.8K | $309.7K |
| Non-cash imputed interest expenses | $32.5K | $32.5K | $34.4K |
| Write-off of accounts receivable | $41.1K | ||
| Unrealized foreign exchange | $212.7K | -$74.5K | $35.8K |
| Write-off of accounts payable | -$805.5K | ||
| Loss on settlement of accounts payable | $139.0K | ||
| Increase in accounts receivable | -$41.1K | ||
| Decrease (increase) in inventory | $20 | $137 | -$11.0K |
| Decrease in prepaid expenses | $41.7K | $16.1K | $201.6K |
| Increase in accounts payable and accrued liabilities | $309.5K | $477.7K | $452.4K |
| Increase in interest payable to related parties | $327.2K | $328.2K | $314.1K |
| Increase in interest payable | $203.3K | $203.3K | $217.3K |
| Net cash used in operating activities | -$1.9M | -$1.5M | -$1.6M |
| Proceeds from lines of credit | $1.8M | $427.8K | $794.5K |
| Proceeds from loan payable | $22.4K | ||
| Proceeds from promissory notes | $1.1M | ||
| Proceeds from exercise of warrants | $6.0K | ||
| Proceeds from sales of ordinary shares | $744.7K | ||
| Net cash provided by financing activities | $1.8M | $1.5M | $1.5M |
| Effect of foreign exchange on cash | -$7.0K | ||
| Change in cash | -$20.4K | -$18.4K | -$89.5K |
Former names
- ALR Technologies SG Pte. Ltd.May 24, 2022 to Sep 23, 20224
Recent filings
- Jun 30, 20266-K
- May 20, 20266-K
- May 15, 20263
- Apr 30, 202620-F
- Apr 9, 20263
- Apr 9, 20263
- Apr 6, 20263
- Apr 6, 20263
- Mar 17, 20263
- Jan 5, 20266-K
- Dec 30, 20256-K
- Dec 30, 20256-K
- Jul 7, 20256-K
- Jun 26, 20256-K
- May 2, 202520-F/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2Yahoo FinanceALRTF quote
- 3
- 4
- 5
- 6
- 7